LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Faiena, Izak"
  2. AU="Petrina Jáuregui, Estrella"
  3. AU="Chiang, Angela"
  4. AU="Balvert, Willemien"
  5. AU="Matic, Nancy"
  6. AU="Cerqueira, Rui"
  7. AU="Greco, Massimiliano"
  8. AU="Dalton, Michelle"
  9. AU="Letard, Sébastien"
  10. AU="Di Gangi, Iole Maria"
  11. AU="Chen, T T"
  12. AU="Alves, Luiz Felipe M F"
  13. AU="Liao, Jing" AU="Liao, Jing"

Suchergebnis

Treffer 1 - 10 von insgesamt 51

Suchoptionen

  1. Artikel ; Online: Multimodal treatments for advanced prostate cancer.

    Faiena, Izak / Kim, Isaac Y / Jang, Thomas L

    Oncotarget

    2019  Band 10, Heft 3, Seite(n) 255–256

    Sprache Englisch
    Erscheinungsdatum 2019-01-08
    Erscheinungsland United States
    Dokumenttyp Editorial
    ZDB-ID 2560162-3
    ISSN 1949-2553 ; 1949-2553
    ISSN (online) 1949-2553
    ISSN 1949-2553
    DOI 10.18632/oncotarget.26525
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Glutamine and the Tumor Immune Microenvironment.

    Faiena, Izak / Ueno, Daiki / Shuch, Brian

    European urology

    2019  Band 75, Heft 5, Seite(n) 764–765

    Mesh-Begriff(e) Glutamine ; Humans ; Immune Evasion ; Interleukin-23 ; Kidney Neoplasms ; Macrophages ; Tumor Microenvironment
    Chemische Substanzen Interleukin-23 ; Glutamine (0RH81L854J)
    Sprache Englisch
    Erscheinungsdatum 2019-01-30
    Erscheinungsland Switzerland
    Dokumenttyp Editorial ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2019.01.015
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma.

    Lebacle, Cedric / Pooli, Aydin / Shuch, Brian / Rao, Nagesh / Chamie, Karim / Kroeger, Nils / Faiena, Izak / Liu, Sandy / Wood, Erika L / Belldegrun, Arie / Drakaki, Alexandra / Pantuck, Allan J

    Cancer investigation

    2024  Band 42, Heft 1, Seite(n) 97–103

    Abstract: Approximately 65% of renal cell carcinomas (RCC) are diagnosed at a localized stage. We investigated the chromosome 5q gain impact on disease-free survival (DFS) in RCC patients. Overall, 676 patients with stages 1-2 RCC and having cytogenetic analysis ... ...

    Abstract Approximately 65% of renal cell carcinomas (RCC) are diagnosed at a localized stage. We investigated the chromosome 5q gain impact on disease-free survival (DFS) in RCC patients. Overall, 676 patients with stages 1-2 RCC and having cytogenetic analysis were included. Gain of 5q was observed in 108 patients, more frequently in clear cell (ccRCC) than non-clear cell tumors. Gain of 5q is likely an independent prognostic factor since the concerned patients had a decreased recurrence risk in stages 1-2 RCC, confirmed in multivariable analysis. Detecting 5q gain could enhance recurrence risk assessment, allowing tailored post-surgery surveillance, and reducing unnecessary treatments.
    Mesh-Begriff(e) Humans ; Carcinoma, Renal Cell/genetics ; Kidney Neoplasms/genetics ; Prognosis ; Disease-Free Survival ; Chromosomes
    Sprache Englisch
    Erscheinungsdatum 2024-02-05
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 604942-4
    ISSN 1532-4192 ; 0735-7907
    ISSN (online) 1532-4192
    ISSN 0735-7907
    DOI 10.1080/07357907.2024.2308172
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel: Intravesical Therapy for Non-muscle Invasive Bladder Cancer-Current and Future Options in the Age of Bacillus Calmette-Guerin Shortage.

    Golla, Vishnukamal / Lenis, Andrew T / Faiena, Izak / Chamie, Karim

    Reviews in urology

    2020  Band 21, Heft 4, Seite(n) 145–153

    Abstract: Non-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial proportion of patients with intermediate- and high-risk disease will progress to invasive bladder cancer and are at a significant risk for metastasis and ... ...

    Abstract Non-muscle invasive bladder cancer (NMIBC) is a common and burdensome malignancy. A substantial proportion of patients with intermediate- and high-risk disease will progress to invasive bladder cancer and are at a significant risk for metastasis and death. Bacillus Calmette-Guerin (BCG) therapy for selected cases has been the standard of care for nearly 40 years. Unfortunately, a world-wide shortage has made BCG challenging to obtain. Furthermore, recurrences and progressions do occur. With the US Food and Drug Administration creating a clear path to drug approval for novel treatments, many therapies have been tested, including intravesical cytotoxic chemotherapy, intravesical immunotherapy, systemic immunotherapy, and novel agents, such as gene therapy and targeted therapy. In this review, we highlight ongoing clinical trials.
    Sprache Englisch
    Erscheinungsdatum 2020-01-16
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2108895-0
    ISSN 2153-8182 ; 1523-6161
    ISSN (online) 2153-8182
    ISSN 1523-6161
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances.

    Movassaghi, Miyad / Chung, Rainjade / Anderson, Christopher B / Stein, Mark / Saenger, Yvonne / Faiena, Izak

    Cancers

    2021  Band 13, Heft 19

    Abstract: The use of immunotherapy has become a critical treatment modality in many advanced cancers. However, immunotherapy in prostate cancer has not been met with similar success. Multiple interrelated mechanisms, such as low tumor mutational burden, ... ...

    Abstract The use of immunotherapy has become a critical treatment modality in many advanced cancers. However, immunotherapy in prostate cancer has not been met with similar success. Multiple interrelated mechanisms, such as low tumor mutational burden, immunosuppressive cells, and impaired cellular immunity, appear to subvert the immune system, creating an immunosuppressive tumor microenvironment and leading to lower treatment efficacy in advanced prostate cancer. The lethality of metastatic castrate-resistant prostate cancer is driven by the lack of therapeutic regimens capable of generating durable responses. Multiple strategies are currently being tested to overcome immune resistance including combining various classes of treatment modalities. Several completed and ongoing trials have shown that combining vaccines or checkpoint inhibitors with hormonal therapy, radiotherapy, antibody-drug conjugates, chimeric antigen receptor T cell therapy, or chemotherapy may enhance immune responses and induce long-lasting clinical responses without significant toxicity. Here, we review the current state of immunotherapy for prostate cancer, as well as tumor-specific mechanisms underlying therapeutic resistance, with a comprehensive look at the current preclinical and clinical immunotherapeutic strategies aimed at overcoming the immunosuppressive tumor microenvironment and impaired cellular immunity that have largely limited the utility of immunotherapy in advanced prostate cancer.
    Sprache Englisch
    Erscheinungsdatum 2021-09-23
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers13194757
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: Survival outcomes in patients with muscle invasive bladder cancer undergoing radical vs. partial cystectomy.

    Chung, Rainjade / Moran, George W / Movassaghi, Miyad / Pohl, Daniel / Ingram, Justin / Lenis, Andrew T / McKiernan, James M / Anderson, Christopher B / Faiena, Izak

    Urologic oncology

    2023  Band 41, Heft 8, Seite(n) 356.e11–356.e18

    Abstract: Purpose: While radical cystectomy (RC) is the standard of care for muscle invasive bladder cancer (MIBC), partial cystectomy (PC) is an effective alternative in select patients. We sought to examine differences in survival for RC and PC in a hospital- ... ...

    Abstract Purpose: While radical cystectomy (RC) is the standard of care for muscle invasive bladder cancer (MIBC), partial cystectomy (PC) is an effective alternative in select patients. We sought to examine differences in survival for RC and PC in a hospital-based registry.
    Material and methods: We identified patients diagnosed with cT2-4 bladder cancer who underwent RC or PC from 2003 to 2015 in the National Cancer Database (NCDB). Using inverse probability treatment weighting (IPTW) to control for known confounders, we compared the primary outcome of overall survival (OS) in patients who underwent RC vs. PC. Kaplan-Meier survival analysis, univariable and multivariable Cox proportional hazards modeling were used. We performed a secondary survival analysis for a subcohort of patients with cT2, cN0, tumor size ≤5 cm, and no concurrent carcinoma in situ (CIS), who may be optimal candidates for PC.
    Results: A total of 22,534 patients met inclusion criteria, of which 6.9% (1,457) underwent PC. RC had longer median OS than PC (67.8 vs. 54.1 months) and on Cox regression analysis (HR 0.88, 95% CI, 0.80-0.95, P = 0.002). However, in our subcohort, there was no difference in OS between RC and PC (HR 1.02, 95% CI, 0.9-1.2, P = 0.74). PC was associated with increased time from surgery to any systemic therapy or death in the subcohort.
    Conclusions: Among patients with clinically organ-confined MIBC, PC appears to afford similar survival outcomes to RC in a large national data set. The safety and tolerability of PC may warrant consideration in highly selected patients.
    Mesh-Begriff(e) Humans ; Cystectomy/adverse effects ; Urinary Bladder Neoplasms/pathology ; Survival Analysis ; Kaplan-Meier Estimate ; Muscles/pathology ; Treatment Outcome
    Sprache Englisch
    Erscheinungsdatum 2023-05-18
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 1336505-8
    ISSN 1873-2496 ; 1078-1439
    ISSN (online) 1873-2496
    ISSN 1078-1439
    DOI 10.1016/j.urolonc.2023.04.017
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Diagnostic biomarkers in non-muscle invasive bladder cancer.

    Faiena, Izak / Rosser, Charles J / Chamie, Karim / Furuya, Hideki

    World journal of urology

    2018  Band 37, Heft 10, Seite(n) 2009–2016

    Abstract: Successful treatment of non-muscle invasive bladder cancer (NMIBC) relies heavily on our ability to accurately detect disease typically in the presence of hematuria as well as to detect the early recurrent tumors in patients with a history of NMIBC. ... ...

    Abstract Successful treatment of non-muscle invasive bladder cancer (NMIBC) relies heavily on our ability to accurately detect disease typically in the presence of hematuria as well as to detect the early recurrent tumors in patients with a history of NMIBC. Unfortunately, the current biomarker landscape for NMIBC is a work in progress. Cystoscopy continues to be the gold standard, but can still miss 10% of tumors. Therefore, physicians frequently use additional tools to aid in the diagnosis of bladder cancer, such as urinary cytology. The urinary cytology is a good option for high-grade disease; however, it is limited by low sensitivity in detecting low-grade disease, as well as variable interpretation among cytopathologists. Thus, the limitations of cystoscopy and urinary cytology have brought to light the need for more robust diagnostic assays. In this non-systematic review, we discuss the performance, potential advantages or disadvantages of these tests, and the future direction of biomarkers in NMIBC.
    Mesh-Begriff(e) Biomarkers, Tumor/analysis ; Humans ; Neoplasm Invasiveness ; Urinary Bladder Neoplasms/blood ; Urinary Bladder Neoplasms/diagnosis ; Urinary Bladder Neoplasms/pathology ; Urinary Bladder Neoplasms/urine
    Chemische Substanzen Biomarkers, Tumor
    Sprache Englisch
    Erscheinungsdatum 2018-11-22
    Erscheinungsland Germany
    Dokumenttyp Journal Article ; Review
    ZDB-ID 380333-8
    ISSN 1433-8726 ; 0724-4983
    ISSN (online) 1433-8726
    ISSN 0724-4983
    DOI 10.1007/s00345-018-2567-1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Re: Adjuvant Sunitinib in High-risk Renal-cell Carcinoma After Nephrectomy.

    Salmasi, Amirali / Faiena, Izak / Drakaki, Alexandra / Pantuck, Allan J

    European urology

    2018  Band 74, Heft 1, Seite(n) 119–121

    Mesh-Begriff(e) Carcinoma, Renal Cell ; Chemotherapy, Adjuvant ; Humans ; Kidney Neoplasms ; Nephrectomy ; Pyrroles ; Sunitinib ; Treatment Outcome
    Chemische Substanzen Pyrroles ; Sunitinib (V99T50803M)
    Sprache Englisch
    Erscheinungsdatum 2018-02-09
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2018.01.036
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy.

    Faiena, Izak / Salmasi, Amirali / Pantuck, Allan J / Drakaki, Alexandra

    European urology

    2018  Band 73, Heft 6, Seite(n) 981

    Mesh-Begriff(e) Abiraterone Acetate ; Androstenes ; Antineoplastic Combined Chemotherapy Protocols ; Humans ; Male ; Prostatic Neoplasms ; Prostatic Neoplasms, Castration-Resistant
    Chemische Substanzen Androstenes ; Abiraterone Acetate (EM5OCB9YJ6) ; abiraterone (G819A456D0)
    Sprache Englisch
    Erscheinungsdatum 2018-02-09
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Comment
    ZDB-ID 193790-x
    ISSN 1873-7560 ; 1421-993X ; 0302-2838
    ISSN (online) 1873-7560 ; 1421-993X
    ISSN 0302-2838
    DOI 10.1016/j.eururo.2018.01.023
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Artikel ; Online: Female Urethral Reconstruction.

    Faiena, Izak / Koprowski, Christopher / Tunuguntla, Hari

    The Journal of urology

    2016  Band 195, Heft 3, Seite(n) 557–567

    Abstract: Purpose: Female urethral reconstruction can be used successfully to treat a heterogeneous group of urethral disorders through an expanding number of unique approaches. Understanding the diverse etiologies of female urethral stricture and loss is ... ...

    Abstract Purpose: Female urethral reconstruction can be used successfully to treat a heterogeneous group of urethral disorders through an expanding number of unique approaches. Understanding the diverse etiologies of female urethral stricture and loss is essential in evaluating and diagnosing patients. Although there is an appreciable body of literature addressing female urethral reconstruction individually, there is a paucity of resources that approach this issue holistically. We discuss the relevant female urethral anatomy, pathophysiology, diagnosis and evaluation of female urethral disorders, and current reconstructive techniques, as well as published outcomes data and potential future directions for female urethral reconstruction.
    Materials and methods: We reviewed articles published in English and indexed in the PubMed®, Embase® and Google Scholar™ databases, and consulted textbooks. Key search terms used were female, urethra, urethral reconstruction, urethroplasty, pathology, stricture, vaginal flap, bladder flap, graft, dilation, pubovaginal sling, catheterization, imaging, tissue engineering and bioscaffold. We created a synopsis of relevant articles, including original research studies and reviews.
    Results: Urethral tissue loss and strictures are caused by traumatic injuries, iatrogenic injuries and, rarely, infections and malignancies. A comprehensive patient history and physical examination are critical for diagnosis. Flexible cystoscopy, voiding cystourethrography and endovaginal magnetic resonance imaging can help to determine the surgical method of repair. Minimally invasive approaches to female urethral reconstruction are associated with poor outcomes. Definitive treatment options for repair of female urethral stricture include vaginal flap/wall urethroplasty, graft urethroplasty and distal urethrectomy with advancement meatoplasty. Repair techniques for urethral loss include primary closure, vaginal flap/wall urethroplasty and bladder flap urethroplasty. Vaginal flap approaches with well vascularized grafts and buccal mucosal grafts have high success rates. Tissue engineered grafts are being investigated as a novel treatment modality.
    Conclusions: Female urethral reconstruction is complex, and one must carefully evaluate patients afflicted with urethral disorders. Urethral stricture and urethral loss have different etiologies. Variations of a standard approach might best address the condition of an individual patient. Long-term outcomes data are not available for contemporary techniques of female urethral reconstruction. The highest success rates have been reported with vaginal flap and buccal mucosal graft urethroplasty. Further studies focusing on newer reconstruction techniques and long-term outcomes are warranted.
    Mesh-Begriff(e) Female ; Humans ; Surgical Flaps ; Urethra/surgery ; Urethral Stricture/surgery ; Urologic Surgical Procedures/methods
    Sprache Englisch
    Erscheinungsdatum 2016-03
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Review
    ZDB-ID 3176-8
    ISSN 1527-3792 ; 0022-5347
    ISSN (online) 1527-3792
    ISSN 0022-5347
    DOI 10.1016/j.juro.2015.07.124
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang